16:30 – 16:40
Introduction
| Miguel Martin, Hospital General Universitario Gregorio Marañón, Madrid, Spain |
16:40 – 18:20
SESSION I: BIOMARKERS
| Chair: | Angel Guerrero, Instituto Valenciano de Oncologia, Valencia, Spain |
| 16:40 - 17:00 | New genomic biomarkers for early breast cancer Aleix Prat, Hospital Clínico de Barcelona, Spain |
| 17:00 - 17:20 | Preemptive DPYD testing for patients planned for fluoropyrimidines Caroline Block, Dana-Farber Cancer Institute, Boston, USA |
| 17:20 - 17:40 | Tumor infiltrating lymphocytes in breast cancer: recent studies and future prospects Roberto Salgado, ZAS Hospitals, Antwerp, Belgium; Peter Mac Callum Cancer Centre, Melbourne, Australia |
| 17:40 - 18:00 | FOXC1 expression could accurately identify basal-like breast cancer within TNBC subtype Partha S. Ray, Onconostic Technologies/3N Diagnostic Group, Evanston, USA |
| 18:00 - 18:20 | Discussion |
18:20 – 18:30
BREAK
18:30 – 20:10
SESSION II: THERAPY OF BREAST CANCER
| Chair: | Carlos Barrios, MD Hospital São Lucas, Brazil |
| 18:30 - 18:50 | Promising new drugs under development in breast cancer Elena Garralda, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain |
| 18:50 - 19:10 | Antibody-drug conjugates in breast cancer: current status Barbara Pistilli, Gustave Roussy, Paris, France |
| 19:10 - 19:30 | Management of patients with high tumor burden metastatic HR+/HER2- Nagi S. El Saghir, American University of Beirut Medical Center, Beirut, Lebanon |
| 19:30 - 19:50 | Recent advances in the adjuvant therapy of HER2-negative early breast cancer Mariana Chavez Mac Gregor, MD Anderson Cancer Center, Houston, USA |
| 19:50 - 20:10 | Discussion |